La Pampa expondrá a la comunidad científica los resultados del Programa de Intervención Monitoreado de Ivermectina

La Pampa, Argentina, Aug 2021
Early treatmentRetrospective · 21,418 patients · Argentina
Ivermectin for COVID-19
La Pampa Argentina · August 2021
Outcome
Improvement
Relative Risk · 95% CI
Mortality
27%0.73 · 0.73–0.73
Death/ICU
38%0.62 · 0.62–0.62
Mortality, >40yo
33%0.67 · 0.67–0.67
Mortality, >40yo w/comorbidities
44%0.56 · 0.56–0.56
no CI
no CI
no CI
no CI
00.511.52+
← Ivermectin
reduces riskIvermectin
increases risk →
Lower mortality with ivermectin

Ivermectin for COVID-19

4th treatment shown to reduce risk in August 2020, now with p < 0.0000000001 from 106 studies, recognized in 24 countries.
Lower risk for mortality, ventilation, ICU, hospitalization, recovery, cases, and viral clearance.

No treatment is 100% effective.
Protocols combine treatments.

6,700+ studies · 220+ treatments

c19early.org
Meta-analysis
News report on the use of ivermectin in La Pampa, Argentina, showing lower mortality with treatment.
This study is excluded in the after exclusion results of meta-analysis: minimal details provided.
Important missing comments or errors? Let us know.
risk of death, 27.4% lower, RR 0.73, treatment 3,269, control 18,149.
risk of death/ICU, 38.0% lower, RR 0.62, treatment 3,269, control 18,149.
risk of death, 33.4% lower, RR 0.67, treatment 3,269, control 18,149, >40yo.
risk of death, 44.0% lower, RR 0.56, treatment 3,269, control 18,149, >40yo including comorbidities.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
La Pampa et al., 10 Aug 2021, retrospective, Argentina, preprint, 1 author, dosage 600μg/kg days 1-5.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org October 2026 Argentina Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Vietnam Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Argentina favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org October 2026 Argentina Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Spain Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Argentina favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0